Vitiligo: a comprehensive overview Part II: treatment options and approach to treatment
- PMID: 21839316
- DOI: 10.1016/j.jaad.2010.10.043
Vitiligo: a comprehensive overview Part II: treatment options and approach to treatment
Abstract
Vitiligo is a common skin disorder that results in depigmentation. With the appropriate management, many patients can minimize disease progression, attain repigmentation, and achieve cosmetically pleasing results. There are numerous medical and surgical treatments aimed at repigmentation; therapies for depigmentation are available for patients with recalcitrant or advanced disease. The use of cosmetics at all stages of treatment may be vital to the patient's quality of life. Understanding all the available options helps choose the appropriate treatment plan and tailor it to your patient. Part II of this two-part series on vitiligo discusses the indications for, evidence behind, and adverse effects associated with many of the therapies used for vitiligo. Both conventional medical and surgical options are discussed in addition to several alternative and promising new therapies.
Copyright © 2010 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.
Comment in
-
Long-term prognosis of vitiligo patients on narrowband UVB phototherapy.J Am Acad Dermatol. 2012 Feb;66(2):326-7. doi: 10.1016/j.jaad.2011.10.022. J Am Acad Dermatol. 2012. PMID: 22243727 No abstract available.
Similar articles
-
Vitiligo surgical, laser, and alternative therapies: a review and case series.J Drugs Dermatol. 2013 Jun 1;12(6):685-91. J Drugs Dermatol. 2013. PMID: 23839187 Review.
-
Vitiligo: new and emerging treatments.Dermatol Ther. 2008 Mar-Apr;21(2):110-7. doi: 10.1111/j.1529-8019.2008.00178.x. Dermatol Ther. 2008. PMID: 18394085 Review.
-
Update on skin repigmentation therapies in vitiligo.Pigment Cell Melanoma Res. 2009 Feb;22(1):42-65. doi: 10.1111/j.1755-148X.2008.00528.x. Epub 2008 Nov 27. Pigment Cell Melanoma Res. 2009. PMID: 19040503 Review.
-
Ultrathin split-thickness skin grafting followed by narrowband UVB therapy for stable vitiligo: an effective and cosmetically satisfying treatment option.Indian J Dermatol Venereol Leprol. 2012 Mar-Apr;78(2):159-64. doi: 10.4103/0378-6323.93632. Indian J Dermatol Venereol Leprol. 2012. PMID: 22421646 Clinical Trial.
-
Vitiligo: an update on current pharmacotherapy and future directions.Expert Opin Pharmacother. 2012 Sep;13(13):1885-99. doi: 10.1517/14656566.2012.712113. Epub 2012 Jul 27. Expert Opin Pharmacother. 2012. PMID: 22835073 Review.
Cited by
-
Sustained Repigmentation in Vitiligo and Leukodermas Using Melanocyte-Keratinocyte Transplantation: 7 Years of Data.Clin Cosmet Investig Dermatol. 2024 Nov 2;17:2447-2457. doi: 10.2147/CCID.S485421. eCollection 2024. Clin Cosmet Investig Dermatol. 2024. PMID: 39507768 Free PMC article.
-
A systematic review of case series and clinical trials investigating systemic oral or injectable therapies for the treatment of vitiligo.Skin Res Technol. 2024 Mar;30(3):e13642. doi: 10.1111/srt.13642. Skin Res Technol. 2024. PMID: 38454597 Free PMC article. Review.
-
Multiple gene-drug prediction tool reveals Rosiglitazone based treatment pathway for non-segmental vitiligo.Inflammation. 2024 Apr;47(2):678-695. doi: 10.1007/s10753-023-01937-9. Epub 2023 Dec 30. Inflammation. 2024. PMID: 38159176 Free PMC article.
-
Efficacy and Safety Comparison of Basic Fibroblast Growth Factor-Related Decapeptide 0.1% Solution (bFGFrP) Plus Oral PUVA Combination Therapy with Oral PUVA Monotherapy in the Treatment of Vitiligo.J Cutan Aesthet Surg. 2023 Jan-Mar;16(1):28-33. doi: 10.4103/JCAS.JCAS_33_21. Epub 2023 Apr 28. J Cutan Aesthet Surg. 2023. PMID: 37383981 Free PMC article.
-
Dermatologic manifestations of thyroid disease: a literature review.Front Endocrinol (Lausanne). 2023 May 12;14:1167890. doi: 10.3389/fendo.2023.1167890. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37251685 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
